Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

ex vivo-expanded autologous T cells IMA101

A preparation of autologous cytotoxic T lymphocytes, specifically recognizing certain tumor-associated antigens (TAAs), with potential antineoplastic activity. The endogenous T cells are isolated, expanded ex vivo, and reintroduced back into the patient. Upon administration, the ex vivo-expanded autologous T cells IMA101 target and kill tumor cells. The T cells are analyzed beforehand for their ability to specifically recognize certain TAAs, based on a proprietary antigen warehouse.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:IMA101 T cells
US brand name:ACTolog IMA101
Code name:IMA101
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search